This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Clinical Trial

. 2020 Jun;145(6):1713-1715.

doi: 10.1016/j.jaci.2020.02.002. Epub 2020 Feb 19.

Severe eosinophilic asthma with nasal polyposis: A phenotype for improved sinonasal and asthma outcomes with mepolizumab therapy

Peter Howarth¹, Geoffrey Chupp², Linda M Nelsen³, Eric S Bradford⁴, Daniel J Bratton⁵, Steven G Smith⁴, Frank C Albers⁶, Guy Brusselle⁷, Claus Bachert⁸

Affiliations

Affiliations

¹ Global Medical, Global Specialty & Primary Care, Brentford, Middlesex, United Kingdom. Electronic address: peter.h.howarth@gsk.com.
² Yale Center for Asthma and Airways Disease (YCAAD), Yale School of Medicine, New Haven, Conn.
³ Value Evidence and Outcomes, GSK, Collegeville, Pa.
⁴ Respiratory Therapeutic Area, GSK, Research Triangle Park, NC.
⁵ Clinical Statistics, GSK, Uxbridge, Middlesex, United Kingdom.
⁶ Respiratory Medical Franchise, GSK, Research Triangle Park, NC.
⁷ Department of Respiratory Medicine, University Hospital Ghent, Ghent, Belgium.
⁸ Upper Airways Research Laboratory, University Hospital Ghent, Ghent, Belgium.

PMID: 32084443
DOI: 10.1016/j.jaci.2020.02.002

Clinical Trial

Severe eosinophilic asthma with nasal polyposis: A phenotype for improved sinonasal and asthma outcomes with mepolizumab therapy

Peter Howarth et al. J Allergy Clin Immunol. 2020 Jun.

. 2020 Jun;145(6):1713-1715.

doi: 10.1016/j.jaci.2020.02.002. Epub 2020 Feb 19.

Authors

Peter Howarth¹, Geoffrey Chupp², Linda M Nelsen³, Eric S Bradford⁴, Daniel J Bratton⁵, Steven G Smith⁴, Frank C Albers⁶, Guy Brusselle⁷, Claus Bachert⁸

Affiliations

¹ Global Medical, Global Specialty & Primary Care, Brentford, Middlesex, United Kingdom. Electronic address: peter.h.howarth@gsk.com.
² Yale Center for Asthma and Airways Disease (YCAAD), Yale School of Medicine, New Haven, Conn.
³ Value Evidence and Outcomes, GSK, Collegeville, Pa.
⁴ Respiratory Therapeutic Area, GSK, Research Triangle Park, NC.
⁵ Clinical Statistics, GSK, Uxbridge, Middlesex, United Kingdom.
⁶ Respiratory Medical Franchise, GSK, Research Triangle Park, NC.
⁷ Department of Respiratory Medicine, University Hospital Ghent, Ghent, Belgium.
⁸ Upper Airways Research Laboratory, University Hospital Ghent, Ghent, Belgium.

PMID: 32084443
DOI: 10.1016/j.jaci.2020.02.002

No abstract available

PubMed Disclaimer

Comment in

Eosinophil paradox with mepolizumab in chronic rhinosinusitis with nasal polyposis.
Lipworth B, Chan R, RuiWen Kuo C. Lipworth B, et al. J Allergy Clin Immunol. 2020 Sep;146(3):683. doi: 10.1016/j.jaci.2020.05.054. Epub 2020 Jul 24. J Allergy Clin Immunol. 2020. PMID: 32713686 No abstract available.
Reply.
Howarth P, Bachert C, Sousa A, Chan R. Howarth P, et al. J Allergy Clin Immunol. 2020 Sep;146(3):683-684. doi: 10.1016/j.jaci.2020.05.053. Epub 2020 Jul 24. J Allergy Clin Immunol. 2020. PMID: 32713687 No abstract available.

Publication types

Actions
Actions
Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Medical